Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Illumina's TruSight One Panel; Life Tech's Certified Exome Services


Illumina has launched its TruSight One sequencing panel, which targets 4,813 genes with known associated clinical phenotypes. The panel is designed to be used in conjunction with Illumina's VariantStudio analysis and reporting software, which will also include new features that expand annotation capabilities such as support to enable family-based filtering, variant classification, and the ability to generate ready-to-use reports.

Life Technologies has added 11 new members to its Ion AmpliSeq Exome Certified Service ProgramSanford Burnham, SeqWright Genomic Services, Genewiz, Affiliated Genetics, Eureka Genomics, the University of Arizona, the University of British Columbia, Ohio State University, AltheaDx, PrimBio Research Institute, and the University of New Mexico.

In order to be certified, the institutions must be able to sequence to exomes on one run of the Ion Proton in two days, using the AmpliSeq Exome Kit, the Proton, and the Ion Reporter software.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.